229 related articles for article (PubMed ID: 36773442)
1. A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
Davoodi-Moghaddam Z; Jafari-Raddani F; Noori M; Bashash D
Transl Oncol; 2023 Apr; 30():101636. PubMed ID: 36773442
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
6. STAT3 Expression and Its Correlation with PD-L1 Expression in Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population.
Hambalie AO; Norahmawati E; Endharti AT; Retnani DP; Rahmadiani N
Adv Hematol; 2024; 2024():7989996. PubMed ID: 38817669
[TBL] [Abstract][Full Text] [Related]
7. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K; Ramaswami R; Mangusan R; Widell A; Ekwede I; George J; Ambinder R; Cheever M; Gulley JL; Goncalves PH; Wang HW; Uldrick TS; Yarchoan R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608378
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
Hatic H; Sampat D; Goyal G
Ann Transl Med; 2021 Jun; 9(12):1037. PubMed ID: 34277837
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials.
Guan J; Zhang J; Zhang X; Yuan Z; Cheng J; Chen B
Medicine (Baltimore); 2022 Dec; 101(50):e32333. PubMed ID: 36550903
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
Liput J; Guler E; Smith DA; Tirumani SH; Hoimes C; Caimi PF; Ramaiya NH
J Comput Assist Tomogr; 2020; 44(4):619-626. PubMed ID: 32558769
[TBL] [Abstract][Full Text] [Related]
12. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
Front Oncol; 2021; 11():662731. PubMed ID: 34221977
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
14. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.
Yang L; Zhao Q; Chen T; Liu W; Qiu X; Chen J; Huang S; Huang R; Dong L
Clin Exp Med; 2023 Nov; 23(7):3767-3780. PubMed ID: 37106265
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
16. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Ciurej A; Lewis E; Gupte A; Al-Antary E
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140246
[TBL] [Abstract][Full Text] [Related]
19. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
20. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
